First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

Clinical trial NCT06799065 · RECRUITING

Trial details

NCT number: NCT06799065
Sponsor: Accent Therapeutics
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors Breast Cancer Recurrent Ovarian Cancer High-grade Serous Ovarian Carcinoma Triple Negative Breast Cancer

Start date: 2025-03-21
Primary completion: 2027-04-30
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.